Interferons are proteins and more specifically glycoproteins (from the cytokine family).

They are originally produced by cells of the immune system, but also by other types of cells depending on the subtypes. 

Interferon comes from the word interfere (prevent, hinder, oppose): these are polypeptides comprising about 160 amino acids, produced naturally by our body to respond to aggression: viruses, bacteria, parasites or tumor cells. There are multiple varieties of interferons (about 300) but the most important are the alpha"α",the beta "β"and the gama "ɣ". There are also other natural interferons, but they can only be taken for cultivation on humans who have not undergone any antibiotic treatment or vaccine. These interferons taken from these people are the "keystones" for all others.

Based on their biological properties and cellular origin, two main types of interferons are distinguishable:

• Type 1 interferons mainly include alpha"α"and beta"β,"secreted primarily by macrophages(α)and fibroblasts (β). Interferon"α"  and interferon "β"  have antiviral, antitumor and anti-proliferative activity: they cause the activation of the synthesis of enzymes inhibiting the replication of viral or cellular DNA. In addition, it causes specific immunity to activate macrophages and NK cells by increasing the expression of antigens.

• The interferon type 2 or gamma "ɣ" is produced mainly by T cells and the cells "Natural Killer" (NK cells) of which the synthesis is stimulated by IGIF (gamma inducing factor): the interferon-gamma "inducing factor ". Gamma interferon "ɣ" is involved in regulating immune and inflammatory responses. It has antiviral and anti-tumor properties and promotes the effects of Interferons alpha "α" and beta "β". It increases the phagocytic activity of macrophages and the expression of antigens. Gamma interferon "ɣ" is used in patients with severe infections. Recombinant "α '' interferon alpha is used in antiviral therapy (hepatitis B and C, Kaposi sarcoma associated with AIDS) and anti-cancer therapy (kidney cancer, melanoma, tricholeucocyte leukemia). Alpha "α," beta (β) and gamma "ɣ" interferons are inducible by the presence of viral genomes; their detections apparently show an ongoing viral infection, without presuming the nature of the virus in question. More generally, alpha interferons "α," beta "β" and gamma "ɣ" can be detected at significant rates (PCR example with an amplification cycle of less than 35). The World Health Organization (WHO) admits that all PCR tests performed for SARS 2 Covid 19 at a higher amplification threshold from 35 cycles or more are invalid (The CDC does not recognize an infection above 28 cycles which means that 90% of declared cases of Covid 19 are not valid) . In addition, how can we set up PCR tests for Covid 19 without any measurement standard, since the sequences have not been isolated. It is for this reason that we do graduate cycles at 35 in order to find a trace of ARN without knowing what it corresponds to since the immune system as soon as you are in contact, even with an Influenza virus will cause interferon proteins: however, this does not prove in any way that you are in the inflammatory phase by Covid 19, for example, since your body is only defending itself, but then one speaks of "cases", though very numerous, but far from being sick. It should be added that with the multitude of variants, the only valid tests are blood or salivary samples. Vaccination does not prevent a new infection with a new variant that will often be generated by a new vaccine.

• Since the discovery of the tiny omega interferon genes in humans about 30 years ago, the tiny omega interferon “ω”  has also been identified in groups of animals: felines, pigs, equines, rabbits, cattle and serotine bats, but has not been found in dogs or mice. Treatment with tiny omega interferon may be effective for patients resistant to interferon alpha "α" because the antigenic structure of the tiny omega interferon "ω" is far from the alpha "α," gamma "β'' and gamma "ɣ " interferons.

Interferon has raised many hopes for the control of many immunological pathologies since its discovery in 1956. 

Interferons are known as one of the key factors of natural origin that can help the immune system solve multiple viral, bacterial, parasitic and oncological pathologies. The three different alpha interferons "α", beta "β" and gamma "ɣ"  have been the subject of extensive research and development in medical applications.

However, despite these long periods of research, the first alpha "α" interferon that was put on the market in the 1980s administered as an injection at doses of multiple million molecular units was applied only in a limited manner because of its toxicity, its price but also its iatrogenic effects. Despite positive results on various degenerative or viral pathologies such as Hepatitis C, multiple sclerosis or corona or retrovirus viruses although usually no retroviruses occur naturally in humans...

As these are molecules of geometric shapes in alpha structures "α" beta (β) and gamma "ɣ": because of their proteolytic degradations, in the gastric environment, the possibility of administration of the various interferons orally had never be considered. 

There were obstacles to overcome: 

• duplication and stabilization

• hydrophobic peculiarity

• Ideal storage at low temperature of 4 degrees Celsius

It was only a few years ago that a group of the Fulmina Institute decided not to adhere to these traditional and restrictive scientific certainties. Indeed, the various interferons including the alpha"α"were identified in human nasal secretions during periods of particular viral pre-infections in China and Hong Kong in 2002 during the epidemic of Severe Acute Respiratory Syndrome (SARS) CoV-1. 

It has been noted that these interferon substances rigorously modulate the immune response.

The Fulmina Institute team persisted in this research by using the alpha "α'' interferon through the membranes of the palate and nasal cavities (rhinopharynx) in infinitesimal doses. The results of these trials revealed that by exposing the lymphatic plexus of oral or nasal mucous tissue in contact with a dose in weak molecular units of interferons, triggered a mechanism of keys of activations but also of stimulations of the immune system during attempts of airborne viral infections giving in some people acute or chronic symptoms (symptomatic or asymptomatic).

Historically, this discovery is not new, but it has been carefully shelved. Indeed, Russian, Chinese, Korean and South American researchers had discovered the therapeutic use of sublingual interferons as early as the early 1960s, long before so-called Western technology manufactured its first commercial variety of interferons. The word interferon was attributed in 1957 by the two researchers: Isaacs and Lindenman.

In 1972, interferon trials were successfully tested against viruses until the 1980s.

These various "atypical" scientific researchers have confirmed that interferons in nasal secretions represent an important defense mechanism as highly effective remedies against viral diseases, capable of transmitting information to the entire immune system chain. These nasal secretions containing interferons do not prove in any way that the person is at the stage of pathology since his body only expresses an immune reaction...

In 1985, in the United States and primarily in Texas, a biotechnology company marketed an oral interferon product to treat viral respiratory infections on cattle and horses in Texas. It was a derivative of interferons β  (beta) of leukocytes: this product has had some success despite the preservation of the unstable product, in tablets.

For problems of scientific and economic battles, this product did not receive the approval of the Food and Drug Administration (FDA) in the United States: endless quarrels ensued to stifle this discovery momentarily.

Later, South American and Cuban scientists increased the purification and production of interferons. They were able to solve the problems of impurities by identifying the active agent. They developed extremely pure alpha interferon varieties and high yields in the 1990s. However, there was still a problem of stabilization and culture (duplication).

As for the Korean researchers, they went further in their research and applications at the time. They could not afford to vaccinate a large portion of the population with hepatitis B, so they isolated an interferon, then stabilized it and administered it sublingually, at a rate of one tablet per day, for cycles of three to seven days. In conclusion, they found that patients had developed immunity to the hepatitis B virus... They therefore understood that it was possible to stabilize vaccines under tablets, which was a considerable good for humanity, especially as the price of the product was reduced. It was no longer necessary to keep it at low temperature: there were no toxic effects.

It was later proven that high doses of injectable dose interferons are no more effective during a viral, acute or chronic infection than an infinitesimal dose.

Indeed, a body whose immune response is considered normal, does not produce thousands of units of interferons.  Good immune responses, during attacks, will indeed produce nasal secretions only at low doses of interferons.

This normal immune-inducing signal is quantifiable in hundreds of molecular units and not in millions of molecular units of interferons, as had been widespread at that time in the scientific community. 

We find ourselves in the same problem today... where some vaccines administered in millions of molecular units cause side and undesirable effects such as variants, for example. It would be enough to stabilize and put in infinitesimal dose tablets in order to have the same desired performance in terms of immune and vaccine response, without the many risks of adverse and perverse effects.

It has become clear that multiple subspecies of interferons from healthy people who have never taken antibiotics and have never received vaccine doses, are capable of producing twenty different subspecies of interferons, which give a very broad spectrum of applications in the field of virology.

Recombinant interferons are only a subspecies. Clinical trials have shown that most recombinant varieties, except that they will be selected specifically for a particular virus, are in infinitesimal doses, whereas the same parent dosage has a notorious toxicity.

We were able to develop a product in tablets with a result, without toxicity, containing two hundred units of interferons for sublingual administration. These tablets are made according to a specific formulation that successfully stabilizes and protects interferon molecules embedded in a vehicular substance of the spagyric carbohydrate complex: these carbohydrates are derived from ancestral trees. A method of duplication (culture) has been designed, allowing us to be as close as possible to the structure of the original strain.

The compound product in its final form acts as a binary formula that only activates when it comes into contact with one of the standard compounds of human saliva. This interferon in this particular mixture acts on sixteen subspecies of interferons simultaneously in cells and sometimes more. This method of preparation, thus represents an essential improvement on the various varieties of interferons. 

The interferon molecule, like many other proteins, has hydrophobic properties (not water-binding) hence its instability when suspended in watery solutions. The interferon molecule, to avoid contact with water, looks for other particles, such as the wall of a vial.

The speed of these watery anti-suspension reactions determines the life of injectable products and their storage at room temperature which has a particular influence on the molecular movement of "Brown". 

Studies have shown that this sublingual method of preparation is effective against a wide variety of viral pathologies. Tests for Herpes Zoster and Simplex, different influenza strains, hepatitis B and C, as well as on a very broad viral spectrum but also on certain types of arthritis, papillomavirus, multiple sclerosis and chronic fatigue syndrome (CFS) which are viral pathologies.

This sublingual preparation has been tested in Kenya, Zimbabwe, Zaire, Uganda, Mexico, the Bahamas, China, the United States, Russia, the United Kingdom and New Zealand. This preparation has been registered as a dietary supplement, without any recognition of therapeutic properties.

In several other studies of many viral pathologies, symptoms such as persistent fatigue, diarrhea and fever, respiratory infections, mucous membrane ulcers and rashes have disappeared with extremely low doses of oral interferons.  After eight to ten days of treatment, 90% of the symptoms were removed. The extension of treatment over eight to ten weeks, with a 500 mg tablet dose containing 150 stabilized units of interferons, showed an increase in cd 4 cell counts in patients whose initial counts were well below 200 CD 4.

It is obvious to many researchers that the lymphoblastoid cells of patients who are atrophied by a few pathological causes, produce very low T cells in active potential: the T cell lacks mechanisms to produce normally robust amounts of interferons.  This leads to acute or chronic viral pathologies.

In addition, research in the United States has shown that very small amounts of interferons prepared in stabilized tablets and taken in sublinguals, have the ability to protect lymphocytes from the invasion of viruses, bacteria and will cover a wide spectrum of fifty-four viruses.

It should be noted that these U.S. researchers found that interferon bucal significantly reduced the contagious transmission of airborne dispersed particles of viruses.

Conclusion: 

The administration of very low doses of alpha "α" beta "β" and gamma "ɣ" sublingual interferons produces a powerful immune modulation effect on a multitude of varieties of viral, degenerative and autoimmune pathologies.

This sublingual dietary supplement is recommended with an appropriate diet. The person should abstain from mint, menthol, pork, cold meat, beef, shellfish, dairy products, sugar and strong spices. The tablet has to be allowed to melt under the tongue gently and should be taken at least one hour before breakfast. 

No toxicity was found during clinical trials. There is no lethal dose (DL 50). 

 Copyright Fulmina Institute

Powered by Froala Editor